Date: 04 Aug 2012
Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
LS women have a 40–60 % lifetime risk of endometrial cancer (EC). Most international guidelines recommend screening. However, data on efficacy are limited.
To assess the performance of OHES for EC screening in LS and compare it with transvaginal ultrasound (TVS) alone.
A prospective observational cohort study of LS women attending a tertiary high-risk familial gynaecological cancer clinic was conducted. LS women opting for EC screening underwent annual OHES and TVS. Histopathological specimens were processed using a strict protocol. Data of women screened between October 2007 and March 2010 were analysed from a bespoke database. Histology was used as the gold standard. Diagnostic accuracy of OHES was compared with TVS using specificity, and positive (PLR) and negative (NLR) likelihood ratios.
Forty-one LS women underwent 69 screens (41 prevalent, 28 incident). Four (three prevalent, one incident) women were detected to have EC/atypical endometrial hyperplasia (AEH), five had endometrial polyps and two had endometrial hyperplasia (EH) on OHES. TVS detected two of four EC/AEH. OHES had similar specificity of 89.8 % (CI 79.2, 96.2 %), but higher PLR 9.8 (CI 4.6, 21) and lower NLR (zero) compared to TVS: specificity 84.75 %(CI 73, 92.8 %), PLR 3.28 (CI 1.04, 10.35) and NLR 0.59 (CI 0.22, 1.58). No interval cancers occurred over a median follow-up of 22 months. The annual incidence was 3.57 % (CI 0.09, 18.35) for EC, 10.71 % (CI 2.27, 28.23) for polyps and 21.4 % (CI 8.3, 40.1) for any endometrial pathology.
Our findings suggest that in LS, annual OHES is acceptable and has high diagnostic accuracy for EC/AEH screening. Larger international studies are needed for confirmation, given the relatively small numbers of LS women at individual centres. It reinforces the current recommendation that endometrial sampling is crucial when screening these women.
Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Moller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Brocker-Vriends AH, Vasen H (2004) Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 127(1):17–25PubMedCrossRef
Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001) MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 19(20):4074–4080PubMed
Lecuru F, Le Frere Belda MA, Bats AS, Tulpin L, Metzger U, Olschwang S, Laurent-Puig P (2008) Performance of office hysteroscopy and endometrial biopsy for detecting endometrial disease in women at risk of human non-polyposis colon cancer: a prospective study. Int J Gynecol Cancer 18(6):1326–1331PubMedCrossRef
Dimitraki M, Tsikouras P, Bouchlariotou S, Dafopoulos A, Liberis V, Maroulis G, Teichmann AT (2011) Clinical evaluation of women with PMB. Is it always necessary an endometrial biopsy to be performed? A review of the literature. Arch Gynecol Obstet 283(2):261–266. doi:10.1007/s00404-010-1601-3 PubMedCrossRef
Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A, Ryan A, Seif MW, Amso NN, Turner G, Brunell C, Fletcher G, Rangar R, Ford K, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Scott I, Jenkins H, Mould T, Woolas R, Murdoch J, Dobbs S, Leeson S, Cruickshank D, Skates SJ, Fallowfield L, Parmar M, Campbell S, Menon U (2011) Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case–control study within the UKCTOCS cohort. Lancet Oncol 12(1):38–48. doi:10.1016/S1470-2045(10)70268-0 PubMedCrossRef
Vasen HF, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Moller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007) Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 44(6):353–362PubMedCrossRef
Kerlikowske K, Smith-Bindman R, Ljung BM, Grady D (2003) Evaluation of abnormal mammography results and palpable breast abnormalities. Ann Intern Med 139(4):274–284PubMed
Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, Muller H, Lynch HT (1994) The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res 14(4B):1675–1678PubMed
Lacey JV Jr, Sherman ME, Rush BB, Ronnett BM, Ioffe OB, Duggan MA, Glass AG, Richesson DA, Chatterjee N, Langholz B (2010) Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 28(5):788–792. doi:10.1200/JCO.2009.24.1315 PubMedCrossRef
- Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS)
Archives of Gynecology and Obstetrics
Volume 286, Issue 6 , pp 1555-1562
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Lynch syndrome
- Endometrial screening
- Outpatient hysteroscopy
- Endometrial sampling
- Industry Sectors
- Author Affiliations
- 1. Department of Gynaecological Oncology, EGA Institute for Women’s Health, Gynaecological Cancer Research Centre, University College London, First floor, Maple House, 149 Tottenham Court Road, London, W1T 7NF, UK
- 2. Department of Gynaecology, University College London Hospital (UCLH), London, UK
- 3. Department of Obstetrics and Gynaecology, ElMinia University Hospitals, ElMinia, Egypt
- 4. Institute of Cancer, Barts and the London School of Medicine and Dentistry, Queen Mary, University of London, London, UK
- 5. Department of Pathology, Cancer Institute, Rockefeller Building, University College London, London, UK
- 6. Department of Radiology, University College London Hospital (UCLH), London, UK